PERSERIS KIT
LOE ApproachingNDASUBCUTANEOUSFOR SUSPENSION, EXTENDED RELEASE
Approved
Jul 2018
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed 10h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERSERIS KIT is a subcutaneous, extended-release formulation of risperidone, a second-generation antipsychotic indicated for schizophrenia and bipolar disorder. This long-acting injection offers monthly dosing convenience compared to daily oral risperidone, improving adherence in patients with psychotic disorders. The mechanism relies on risperidone's dopamine D2 and serotonin 5-HT2A receptor antagonism delivered via a proprietary subcutaneous depot technology.
LOE Approaching1.5 years to LOE
Product approaching loss of exclusivity in 1.7 years with limited publicly available commercial data; brand team likely focused on market retention and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Worked on PERSERIS KIT at Indivior? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.